Posted by Michael Wonder on 29 Sep 2016
CADTH posts final recommendation for Zydelig
29 September 2016 - CADTH has published its final recommendation for Zydelig for follicular lymphoma.
CADTH has not recommended the use of idelalisib for the treatment of patients with follicular lymphoma who have received at least two prior systemic therapies and are refractory to both rituximab and an alkylating agent. The Expert Review Committee was not convinced that idelalisib has a net clinical benefit when compared with best supportive care.
